How many investments has SV Health Investors made?

SV Health Investors has 231 tracked investments, 15 of which have exited, including 13 dated in the last 24 months.

What stage does SV Health Investors invest at?

SV Health Investors invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is SV Health Investors's typical check size?

SV Health Investors typically writes checks of $1M – $20M.

What sectors does SV Health Investors focus on?

SV Health Investors focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is SV Health Investors located?

SV Health Investors is headquartered in Boston, US.

Does SV Health Investors lead rounds?

Yes, SV Health Investors leads investment rounds.

Who does SV Health Investors co-invest with?

SV Health Investors most often shares deals with Sanofi Ventures, Ascension Ventures, MRL Ventures Fund, among 138 tracked co-investors.

SV Health Investors

Venture capital

Boston · Pre-Seed–Late Stage · 30 people tracked

Also known as SV HEALTH INVESTORS, LLC · SV HEALTH MANAGERS LLP

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into SV Health Investors

4,005 people in our graph share verified history with the SV Health Investors team — schools, employers, funds. One of them is your warm intro.

James Detweilerunlockedknows Robert Haybittel · together at Morgan Stanley (overlapped)

×2knows the team · via McKinsey & Company

×2knows the team · via Morgan Stanley

×2knows the team · via Harvard Business School

knows the team · via Harvard University

×2knows the team · via Colby College

✨ Fox Verdict

Investment thesis

SV Health Investors pursues a proven, adaptable strategy for selecting healthcare investments and creating value. The firm invests across different stages, geographic regions and sectors, with particular expertise in biotechnology, dementia, medical devices, and healthcare services. It emphasizes a long track record of consistent performance built over decades, positioning itself to respond to the evolving demands of the healthcare industry.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Boston Europe Global London North America United Kingdom United States

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $20M

Boston, Massachusetts, US

Leads rounds

Leads

Instruments

Equity

Founded

2013

Last 12 months

8 investments

AUM

$1.1B

VC funds

Tracked investments

231

Unicorns

IPOs

Acquisitions

Team · 30 people

from the firm's website & curated & public directories

Aaron Sandoski· MCF Partner· Greater Bostonin

Partner on the Medtech Convergence Fund team.

a•••@norwichventures.comreveal

Greg Madden· Managing Partner· Boston, Massachusettsin

Managing Partner working across Medtech and Healthcare Growth investing.

g•••@svhealthinvestors.comreveal

Paul LaViolette· Managing Partner· Boston, Massachusettsin

Managing Partner focused on the firm's Medtech investing.

p•••@svhealthinvestors.comreveal

A.J. Rossi· Partner· Boston, Massachusetts, United States

A.J. Rossi serves as Vice President of Legal Affairs and Chief Compliance Officer at Ridgewood Energy, with over two decades of experience in legal and regulatory compliance. His responsibilities include managing compliance programs, corporate governance, and private equity fund management, with a focus on SEC regulations and contract negotiations. Prior to Ridgewood Energy, Rossi worked at Bryan Cave.

a•••@svhealthinvestors.comreveal

Brent Faduski· Chief Financial Officer, Chief Compliance Officer and Partner· Winchesterin

Brent Faduski is CFO, Chief Compliance Officer, and Partner at SV Health Investors, which he joined in 2008, overseeing the firm's finance and accounting functions. He previously served as Controller at CMGI @Ventures and as a Senior Associate in the Technology Group at PricewaterhouseCoopers, where he worked with early-stage venture-backed companies and venture funds.

b•••@svhealthinvestors.comreveal

Kate Bingham· Managing Partner· London, England, United Kingdomin

Kate Bingham co-leads the biotech franchise at SV Health Investors, focusing on drug discovery and development companies across the UK, EU, and US, and has led many of the firm's company-creation investments. She chaired the UK Vaccine Taskforce, for which she was awarded a DBE in 2021, and holds a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School. She also serves on the boards of the Francis Crick Institute and ARIA.

k•••@svhealthinvestors.comreveal

Michael Balmuth· Managing Partner· Boston, Massachusettsin

Michael Balmuth joined SV Health Investors in 2014, where he focuses on digital health and healthcare technology services, including provider and payer technology, telehealth, healthcare analytics, and pharmaceutical/clinical trial software. He previously held operating roles in healthcare technology and spent over 20 years in growth equity investing, including as a General Partner at Summit Partners and as head of healthcare IT investments at Edison Partners, along with earlier leadership roles at IBM. He holds an AB in Engineering Sciences from Dartmouth College and an MBA from Harvard Business School.

m•••@svhealthinvestors.comreveal

Mike Ross· Partner· San Mateo, Californiain

Mike Ross joined SV Health Investors as a Venture Partner in 2001 and became Managing Partner in 2002, where he leads biotech investments and activities in the US and co-leads the firm's biotech franchise. Before SV, he spent 13 years at Genentech as its tenth employee, holding roles including Vice President of Development and Vice President of Medicinal and Biomolecular Chemistry, and was Founding CEO of Arris Pharmaceutical. He holds an AB from Dartmouth College, a PhD in Chemistry from Caltech, and completed an NIH Post-Doctoral Fellowship in Molecular Biology at Harvard.

m•••@svhealthinvestors.comreveal

Nikola Trbovic· Managing Partner, Biotech team· New York City Metropolitan Areain

Nikola Trbovic joined SV Health Investors in 2022 as a Managing Partner on the Biotech team. He was previously a Partner at Pfizer Ventures, where he invested in emerging companies developing new medicines, and earlier held roles in R&D technology investments, R&D strategy, and early clinical portfolio management at Pfizer. Before Pfizer, he was an Associate Principal at McKinsey & Co. in the Pharmaceuticals Practice, and he holds a PhD in Biochemistry and Molecular Biophysics from Columbia University and a Diplom in Biochemistry from Goethe University Frankfurt.

n•••@svhealthinvestors.comreveal

Tom Flynn· Managing Partner· Boston, Massachusettsin

Tom Flynn invests in growing health care companies with a primary focus on health care services, including outpatient provider services and clinician-support outsourcing businesses. Before joining SV Health Investors, he was a partner at healthcare growth capital investor Ferrer Freeman & Co. and earlier held investing roles at GE Capital and Prudential Investment Corporation. He holds an AB in Economics from Holy Cross College and an MBA from Harvard Business School.

t•••@svhealthinvestors.comreveal

Jamil Beg· Partner· Cambridge, Massachusettsin

Magnus Hildingsson· Partner· Greater Sydney Area

m•••@pemba.com.aureveal

Nikola· Managing Partner· New York City Metropolitan Area

Founding partner of Apiary Capital, a UK private equity firm focused on business, financial, technology, education and healthcare services. Previously COO at Bowmark Capital and Duke Street and a founding partner at Park Square Capital.

Robert Haybittel· Chief Financial Officer and Partner· Greater Sydney Areain

r•••@pemba.com.aureveal

Sasa Vucinic· Managing Partner· South Koreain

Sasa chairs NBM's Investment Committee. He previously co-founded and led the Media Development Loan Fund, a mission-driven fund providing debt and equity financing to independent media in the developing world, deploying USD 100 million over 16 years. Earlier he was a journalist in Yugoslavia, serving as the first CEO of Radio B-92 in Belgrade and Editor in Chief of the magazine NON.

Shana Hudes· Managing Partner· Francein

s•••@iris.vcreveal

Christian Jung· Partner· London, England, United Kingdomin

c•••@svhealthinvestors.comreveal

Miles Gerson· Partner· USAin 𝕏

Miles Gerson joined SV Health Investors as a partner in 2026 and co-leads the firm's Dementia Discovery Fund (DDF). He previously headed Takeda Ventures, where he oversaw a portfolio of more than 60 private and public life sciences investments and led the corporate venture group's global investment strategy, and also served on an interim basis as Takeda's Head of GI Business Development. Earlier in his career he was in founding management of early-stage companies and led investment diligence for venture and private equity firms in the US and Europe. He holds a JD/MBA from the University of Wisconsin-Madison and Bachelor's and Master's degrees in Neuroscience & Behavioral Studies from Wesleyan University.

Charles Dunn· Principal· Londonin

Charles Dunn joined SV Health Investors in 2018 as a Principal on the biotech team, where he helps form and fund companies developing new medicines across early creation to later-stage public and private opportunities. Before SV he qualified as an ACA after three years at Deloitte serving Life Sciences clients, and has an academic background in human genetics and molecular biology from UCL.

c•••@svhealthinvestors.comreveal

Dirk Landgraf· Principal· Boston, Massachusettsin

Dirk Landgraf joined SV Health Investors in 2020 and is a Principal on the Dementia Discovery Fund (DDF) team, where he helps form and fund companies developing new medicines for dementia and supports DDF portfolio companies with due diligence and strategic, business development, and operational needs. Before SV, he was an Associate Director in the External Innovation group at Biogen in Cambridge, MA, evaluating business development opportunities across neurological therapeutic areas, and earlier was a Postdoctoral Fellow in Susan Lindquist's lab at the Whitehead Institute at MIT. He holds a PhD from Harvard University's Department of Systems Biology at Harvard Medical School and BSc and MSc degrees in Biochemistry from the Technical University of Munich.

Hannah Maunder· Investor Relations and Communications Associate· United Kingdomin

Serves as the firm's press contact, handling investor relations and communications.

h•••@svhealthinvestors.comreveal

Alex Badamchi-Zadeh· Senior Associate· Londonin

Alex Badamchi-Zadeh is a biotech investor at SV Health Investors, managing positions across the SV7 Impact Medicine Fund, Biotech Crossover Opportunities Fund, and SV8 Bio Fund, and serves as an investment committee member for Cancer Research Horizons. Previously, he held business development and strategy roles at Xilio Therapeutics, a NASDAQ-listed immuno-oncology company, and worked as a life science strategy consultant at L.E.K. Consulting. His background includes immunology research at Harvard Medical School, Imperial College London, and the University of Oxford, with publications in Nature, Science Immunology, and In Vivo.

a•••@svhealthinvestors.comreveal

Andrew Cappetta· Vice President· Bostonin

Andrew Cappetta joined SV Health Investors in 2022 as an Associate on the Healthcare Growth Team and advanced to Senior Associate in 2024 and Vice President in 2025. Before SV, he worked on Thermo Fisher Scientific's Corporate Development team, focusing on M&A of healthcare and life science companies, where he executed two transactions totaling $550 million. He holds a B.S. in Business Administration: Finance from the University of New Hampshire.

a•••@svhealthinvestors.comreveal

Eugene Hill· Investor· Boston, Massachusettsin

Gene Hill joined SV Health Investors in 1999 and focuses on health care services and healthcare IT services investments. Before SV, he spent five years as a Partner at Accel Partners in Palo Alto, where he handled early-stage healthcare service and HCIT investments, and previously held senior management roles including President of Behavioral Health at United HealthCare Corporation, CEO and President of US Behavioral Health, and President and Chairman of Sierra Health and Life Insurance Company. He holds a BA from Middlebury College and an MBA from Boston University.

e•••@svhealthinvestors.comreveal

Freya Easton· Associate

f•••@svhealthinvestors.comreveal

Alan Foster· Vice President· San Mateo, California, United Statesin

Alan Foster joined TeleSoft in 2004 and has over 25 years of experience in venture capital, engineering, and product management. As Managing Director he focuses on semiconductors, systems, and software investments, and has served on or observed the boards of VoiceObjects, Education.com, and Calient Technologies.

a•••@telesoftvc.comreveal

Amer Ramzan· Vice President· Copenhagen, Capital Region of Denmark, Denmarkin

Leads Promentum, combining top-tier consulting experience with a background in boards, advisory and venture capital; his role is to anchor quality and cohesion across the platform.

a•••@promentumequity.comreveal

Georgia Frost· Vice President· UKin

Georgia Frost is a Vice President at SV Health Investors, working on the investment team for the Dementia Discovery Fund. The Dementia Discovery Fund is a venture capital fund focused on early-stage biotech companies developing therapeutics for dementia, and it is managed by SV Health Investors, a life sciences venture capital and growth equity firm.

Georgia Frost· Vice President· London Area, United Kingdomin

Georgia Frost is a Vice President on the investment team of the Dementia Discovery Fund (DDF), a venture capital fund focused on early-stage biotech companies developing therapeutics for dementia. DDF is managed by SV Health Investors, a life sciences venture capital and growth equity firm.

g•••@svhealthinvestors.comreveal

Tim Harris· Vice President· USA

Founder mafia

5 people who came through SV Health Investors went on to found or lead other companies.

Jamil BegPartnerFounded Nido Biosciences +1 Jonathan BehrPartnerFounded Tilos Therapeutics +1 Susan HillVenture PartnerFounded Mestag Therapeutics +1 Olivia CavlanInvestment PrincipalFounded Alchemab Therapeutics Alex LeechVenture PartnerFounded Forth Therapeutics

What they invest in

from 102 of 231 portfolio companies

Healthtech ×70Biotech ×64Medical Devices ×48Digital Health ×24Deep Tech ×19AI & Machine Learning ×15Hardware ×9Longevity ×5

HQs:United States×71United Kingdom×8Canada×1Germany×1Ireland×1

Who they back

founder profiles across 39 portfolio companies

46%

solo founders

18 of 39 mapped founding teams

23%

repeat founders

of 43 founders with career history

~4 yrs

old at investment

median across 19 dated deals

Founding team size:solo founder×182 founders×153 founders×14+ founders×5

Where their founders studiedfrom 41 founders with education data

University of California, Berkeley ×4University of Cambridge ×3Dartmouth College ×2Harvard University ×2Massachusetts Institute of Technology ×2Stanford University ×2Thayer School of Engineering at Dartmouth ×2The Hebrew University of Jerusalem ×2

What their founders studiedfrom 37 founders with field-of-study data

Engineering ×12Life Sciences ×10Medicine ×6Economics ×4Finance & Accounting ×3Business & Management ×2Chemistry ×2Computer Science ×2

Where their founders worked beforefrom 43 founders with career history

GlaxoSmithKline ×3Alzheimer's Research UK ×2Avizia ×2BioInnovate Ireland ×2Faculty ×2Goldman Sachs ×2Jpmorganchase ×2Pfizer ×2

21 founders hold a PhD · 5 hold an MBA (of 40 with degree data)

Investments · 231 tracked

founders shown can be your intro path

By year:2026 · 6 2025 · 7 2024 · 3 2022 · 8 2020 · 3 2019 · 6 2018 · 4 2017 · 1 2016 · 6 2015 · 2 2014 · 5 2013 · 259 dated

AdaptHealthadapthealth.comNASDAQ: AHCO

AdaptHealth provides home healthcare supplies and services, delivering equipment for sleep apnea (CPAP/PAP), respiratory and breathing support, mobility, and diabetes care directly to patients' homes.

Digital HealthHealthtechMedical Devices

Suzanne Foster(Chief Executive Officer)in

Co-investorsOne Equity Partners

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsForesite Capital Mission Bay Capital Mission Biocapital MRL Ventures Fund Polaris Partners

American Well inNYSE: AMWL

American Well operates a digital healthcare platform that connects patients, physicians, and healthcare professionals to provide remote clinical services, earning revenue through arrangements with healthcare organizations and clients who use its technology to deliver telehealth and related services.

HealthtechBoston, US

Ido Schoenberg(Executive Officer, Director)in Roy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)Phyllis Gotlib(President, International)inMark Hirschhorn(Executive Vice President, Chief Financial Officer and Chief Operating Officer)in

Co-investorsHanaco Venture Capital Martin Ventures SV Life Sciences

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCMay 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)inKEVIN LEE(Executive Officer, Director)in NIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Longwood Fund SR One Capital Management Vertex Ventures HC +2 more

Cytomed TherapeuticsNASDAQ: GDTC

Insuletinsulet.com inNASDAQ: PODD

Insulet develops the Omnipod, a tubeless, wearable, disposable insulin delivery Pod, along with automated insulin delivery systems for people managing insulin-dependent diabetes.

Digital HealthHardwareHealthtechMedical DevicesActon, US

Ashley A. McEvoy(Director, President and Chief Executive Officer)in Flavia Pease(Executive Vice President and Chief Financial Officer)in Eric Benjamin(Executive Vice President, Chief Operating Officer)inLisa Blair Davis(Senior Vice President, Chief Human Resources Officer)inMichael H. Panos(Executive Vice President, Chief Commercial Officer)

Co-investorsWinklevoss Capital

Pulse BiosciencesNASDAQ: PLSEMay 2026 · $13M

Pulse Biosciences develops and commercializes ablation systems based on nanosecond pulsed-field ablation technology to treat medical conditions including benign skin lesions, soft tissue tumors, and cardiac arrhythmias.

BiotechBurlingame, US

Brian B. Dow(Executive Officer)Darrin R. Uecker(Executive Officer, Director)Amy Wang(Executive Officer, Director)Paul A. LaViolette(President and Chief Executive Officer)

BoardMaky Zanganeh(Director)Christopher Marlett(Director)

Sutrobiosutrobio.com in 𝕏NASDAQ: STRO

Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.

BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US

William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)in Hans-Peter Gerber(Chief Scientific Officer)in David Pauling(Chief Administrative Officer and General Counsel)in Jonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in

Co-investorsOwl Capital Samsara BioCapital Solasta Ventures Vida Ventures

Xilio Therapeuticsxiliotx.com inNASDAQ: XLOSeries A · Sep 2018 · $30M

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +9 more

Spectrawavespectrawave.com in 𝕏Sep 2024✓ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in

Board seat Paul LaViolette· per SEC Form D

Co-investorsLumira Ventures S3 Ventures Deerfield Management Company Johnson & Johnson Innovation – JJDC

Alchemab Therapeuticsalchemab.com in 𝕏Series A · Sep 2025 · $32M✓ verified

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

Jane Osbourn(Chief Executive Officer)

Co-investorsDCVC Bio RA Capital Dementia Discovery Fund Lightstone Ventures Ono Venture Investment, Inc.British Business Bank +2 more

Draig Therapeuticsdraigtherapeutics.com in✓ verified

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)in Simon Ward(Chief Scientific Officer & Founder)in

Partner Charles Dunn· led

Co-investorsAccess Biotechnology Canaan Partners Sanofi Ventures SR One Capital Management British Business Bank Janus Henderson Investors

Dualitas Therapeuticsdualitastx.com inJul 2025✓ verified

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in

Board Alicia Levey(Director)Michael Ross(Director)

Co-investorsQiming Venture Partners Versant Ventures Alexandria Dementia Discovery Fund Qiming Healthcare Qiming Venture Partners USA

Ebt Medicalebtmedical.com in 𝕏Series A · Nov 2019 · $10M✓ verified

EBT Medical develops neuromodulation technologies targeting the Saphenous nerve to treat pelvic health disorders, particularly overactive bladder.

BiotechMedical Devices

Paul Yoo(Co-founder, President & Chief Scientific Officer)in Sasha John(Co-founder and Chief Innovation Officer)in Keith R Carlton(Chief Executive Officer)in

Co-investorsGenesys Capital Toronto Innovation Acceleration Partners

Harness Therapeutics Ltdharnesstx.com in✓ verified

Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.

BiotechHealthtech

Jan Thirkettle(CEO Director)in

Co-investorsEpidarex Capital Ono Venture Investment, Inc.Dementia Discovery Fund

Mestagmestagtherapeutics.com in 𝕏✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)in

Co-investorsForbion GV (Google Ventures)Northpond Ventures

Mestag Therapeuticsmestagtx.com in 𝕏Mar 2026 · $40M✓ verified

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGV (Google Ventures)Forbion Johnson & Johnson Innovation – JJDC Northpond Ventures JJDC

NRG Therapeuticsnrgtherapeutics.com in✓ verified

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)in Claus Sundgreen(Chief Medical Officer)in Paul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCriteria Bio Ventures Novartis Venture Fund British Business Bank M Ventures Dementia Discovery Fund

Packaging Compliance Labspkgcompliance.com in✓ verified

Packaging Compliance Labs is an industry leader providing sterile packaging solutions, design validation, and contract packaging services for medical device and life sciences manufacturers.

Advanced ManufacturingEnterprise SoftwareMedical DevicesSaaSGrand Rapids, US

Matthew Lapham(CEO & Co-Founder)in

Sitryxsitryx.com in 𝕏✓ verified

Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.

BiotechDeep TechHealthtech

Co-investorsLongwood Fund Oxford Science Enterprises Sofinnova Partners

Therini Biotherinibio.com inSeed · Jul 2019 · $9M✓ verified

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

BiotechDigital HealthHealthtechMedical DevicesSacramento, US

Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in

Board Olga Danilchanka(Director)inLaia Crespo-Martin(Director)

Co-investorsMRL Ventures Fund Sanofi Ventures Angelini Ventures Mitsui Global Investment Apollo Health Ventures Dementia Discovery Fund +2 more

visit https://trimtechtherapeutics.comtrimtechtherapeutics.com in✓ verified

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

BiotechDeep TechLongevityMedical DevicesCambridge, GB

Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)

Co-investorsCambridge Innovation Capital Pfizer Ventures Pfizer Venture Investments

visit www.enarabio.comenarabio.com in 𝕏✓ verified

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsPfizer Ventures RA Capital Samsara BioCapital Pfizer Venture Investments M Ventures

Axon Therapiesaxontherapies.comApr 2016SEC filingmedium confidence

Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).

HealthtechMedical DevicesNew York, US

Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)

Board seat Paul LaViolette· per SEC Form D · $2M raise · filed Apr 2016

Co-investorsDeerfield Management Company Earlybird Venture Capital

CardioFocuscardiofocus.com in 𝕏Series C · May 2016 · $31M

CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.

BiotechHealthtechMedical DevicesMarlborough, US

Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)in Anjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephan S. Ogilvie(CEO)in

Board seat Paul LaViolette· per SEC Form D

Co-investorsBioBrit

Csa Medical Increjuvenair.com inSeries B · Jun 2026 · $21M

RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.

HealthtechMedical DevicesLutherville, US

Ellen Sheets(Executive Officer, Director)inIan J. Vawter(Executive Officer)Steven Schaefer(Executive Officer)inWilliam Floyd(Executive Officer, Director)inVincent Owens(Director)Richard Kent(Director)

Board seat Paul LaViolette· per SEC Form D

Co-investorsAscension Ventures First Analysis New Markets Venture Partners

Endotronixendotronix.com in 𝕏Series C · Jul 2016 · $37M

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

Harry Rowland(Executive Officer, Director)inAnthony I Nunez(Executive Officer, Director)inAnthony A. Nunez(Executive Officer, Director)inAnthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)

Board seat Paul LaViolette· per SEC Form D

Co-investorsBioventures Investors Jumpstart Ventures Lumira Ventures OSF Ventures Seroba Life Sciences LSP (Life Sciences Partners)

Lunair Medicallunairmedical.com inAug 2025

Lunair Medical develops an implantable closed-loop system that senses respiration and stimulates the phrenic nerve to treat moderate-to-severe sleep apnea, avoiding masks, mouthpieces, and wearables.

Digital HealthHealthtechMedical DevicesMinneapolis, US

Mark Christopherson(Executive Officer, Director)inHoward Levin(Director)

BoardDavid Neustaedter(Director)inMichael Hurley(Director)

Board seat Paul LaViolette· per SEC Form D

Ocular Therapeutix Nasdoculocutx.com in 𝕏Mar 2019

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.

BiotechDigital HealthHealthtechMedical DevicesBedford, US

Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDonald Notman(Executive Officer)in

Board seatCharles Warden· per SEC Form D

Co-investorsAscension Ventures Sofinnova Ventures Top Corner Capital Agent Capital

Stimwave Technologiesstimwave.comAug 2020SEC filingmedium confidence

BiotechHealthtechPompano Beach, US

Laura Tyler Perryman(Director)Regina Groves(Executive Officer, Director)Virginia Sullivan(Executive Officer)Marc Loev(Director)Richard Chen Mao(Director)Gary Perryman(Director)

Board seat Paul LaViolette· per SEC Form D · $8M raise · filed Sep 2020

Co-investorsEmergent Medical Partners, LLP

TransEnterixtransenterix.com inSep 2017

Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.

AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US

Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)

Board seat Paul LaViolette· per SEC Form D

Co-investorsAisling Capital Quaker BioVentures SV Life Sciences

ValenTxvalentx.comSeries B · Jul 2014 · $22M

BiotechMaple Grove, US

JON PATRICK ST. GERMAIN(Executive Officer)DAVID KRENN(Executive Officer)JOHANN NEISZ(Executive Officer, Director)

BoardMARY LINCOLN CAMPBELL(Director)MITCHELL DANN(Director)PAUL A. LAVIOLETTE(Director)in

Board seat Paul LaViolette· per SEC Form D

Co-investorsKaiser Permanente Ventures

0 2 AstronauTxastronautx.bio in

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsMPM BioImpact Novartis Venture Fund UCL Technology Fund AlbionVC

31 Quell Therapeuticsquell-tx.com

Quell Therapeutics is a clinical-stage biopharmaceutical company developing targeted Treg cell therapies with advanced manufacturing capabilities.

BiotechDeep TechHealthtechMedical Devices

Co-investorsAlbionVC Jeito Capital UCL Technology Fund

Achillion Pharmaceuticals, Inc.achillion.com in 𝕏

Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.

BiotechHealthtech

Co-investorsConnecticut Innovations Pappas Capital Domain Associates

Adimabadimab.com in

Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.

AI & Machine LearningBiotechDeep TechVermont, US

Co-investorsGrandBanks Capital LaunchCapital Lux Capital Mithril Capital Management Premji Invest OrbiMed +1 more

AdvanCelladvancell.com.au inSeries C · Jun 2026 · $110M

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)in Aaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Catalio Capital Management, LP Proto Axiom Tenmile Abingworth Ally Bridge Group +2 more

Ally Bridgeally-bridge.com

Ally Bridge Group is a healthcare investment management firm investing across the global life sciences industry through complementary private equity and public equity strategies.

BiotechHealthtechMedical DevicesNew York, US

Frank Yu(Founder, Chief Executive Officer, Chief Investment Officer)in

Alpheus Medicalalpheusmedical.com in

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.

BiotechHealthtechMedical DevicesChanhassen, US

Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)

BoardKlaus Veitinger(Director)in Imran Eba(Executive Officer)in

Co-investorsOrbiMed HealthQuest Capital Samsara BioCapital Action Potential Venture Capital Ltd.

Amphistaamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)in Giles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life Sciences Novartis Venture Fund Dementia Discovery Fund European Investment Fund Forbion Gilde Healthcare +2 more

Artios Pharmaartios.com in 𝕏Nov 2025 · $115M

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners M Ventures Novartis Venture Fund Pfizer Venture Investments RA Capital Sofinnova Partners +2 more

Avitideavitide.com inSeries A · Mar 2013 · $1Macquired by Repligen

Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.

BiotechHardwareMedical DevicesLebanon, US

Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsOrbiMed Borealis Ventures Mithril Capital Management Polaris Partners Sands Capital Ventures SV Life Sciences

AvroBio, Inctheavrobio.org in 𝕏

AVROBIO develops ex vivo lentiviral vector-based hematopoietic stem cell gene therapies to treat lysosomal disorders by permanently integrating therapeutic genes into patient stem cells manufactured outside the body.

BiotechDigital HealthHealthtechMedical Devices

Bardybardydx.com inAcquired

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPERTURE Venture Partners Aphelion Capital Ascension Ventures Lumira Ventures RC Capital Rex Health Ventures +1 more

Brixtonbrixtonbio.com

Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration.

BiotechMedical Devices

Charles Sidoti(Founder)in

Co-investorsAngel Physicians Fund Excelestar Ventures FemHealth Ventures Schooner Capital

Carawaycarawaytx.com in 𝕏acquired by Merck

Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.

BiotechHealthtech

Co-investorsEisai Innovation, Inc.MRL Ventures Fund

CarePredictcarepredict.com in 𝕏

CarePredict offers a platform that detects patterns in the daily activities of older adults to signal health changes and enable early intervention.

AI & Machine LearningDigital HealthHealthtechLongevityPlantation, US

Satish Movva(Founder)inPeter Livingston(Director)Dean Hatton(Director)inMarc Loev(Director)

Co-investorsHealthtech Capital Las Olas Venture Capital Village Global Miami Angels

Celerioncelerion.com in

Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients.

BiotechDigital HealthHealthtechMedical DevicesLincoln, US

Co-investorsAea Investors H.I.G. Capital H.I.G. HealthBridge Partners

Cerevancecerevance.com in 𝕏

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)in Sagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)in Ottavio V. Vitolo(Chief Medical Officer)in

Co-investorsForesite Capital GV (Google Ventures)Dementia Discovery Fund SV Life Sciences Dementia Discovery Lightstone Ventures +3 more

eMed Technologiesemedtc.com in

EMED makes infusion pump systems and subcutaneous delivery devices for patients requiring immunoglobulin therapy and other biologics.

Digital HealthHardwareHealthtechMedical Devices

Phil Parvin MBAin

EPIVAX, INC.epivax.com

EpiVax works with biologic and vaccine developers to assess and manage immunogenicity risk across the product lifecycle, combining in silico analysis with in vitro testing to produce actionable immunogenicity data.

AI & Machine LearningBiotechHealthtech

Annie De Groot MD(Founder)inRich-Henry Schabowsky, PhD, JDin

Evelo Biosciences in

BiotechCambridge, US

Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)in William DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)

BoardNoubar B. Afeyan, Ph.D.(Director)

Co-investorsFlagship Pioneering Kaiser Permanente Ventures

Evidation Healthevidation.com in 𝕏Series C · Aug 2018 · $30M

Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.

BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US

Christine Lemke(Executive Officer, Director)inDeborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein

BoardDavid Fleshman(Director)Rowan Chapman(Director)in

Co-investorsAsset Management Company B Capital Group B4 Capital Cross Creek Advisors Fresco Capital G Squared +5 more

Eyebiotecheyebiotech.comSeries A · Feb 2022 · $65M

EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.

BiotechHealthtechHolborn, London

David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)

Co-investorsJeito Capital Omega Funds

Homecare Homebasehchb.com in

Homecare Homebase (HCHB) offers a suite of AI and analytics extensions built into its home health and hospice software, providing reporting dashboards, patient intake, rehospitalization risk prediction, automated scheduling, and ambient clinical documentation.

AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechMedical DevicesSaaS

Dr. Martha Stuart Williams(Chief People Officer)Isaac(Vice President of Technology Operations)

Imbriaimbria.com inNov 2025 · $57.5M

Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.

BiotechDigital Health

Alvin Shih(CEO)in Albert M. Kim(Chief Medical Officer)in

Co-investorsAN Venture Partners Catalio Capital Management, LP RA Capital Sanofi Ventures Catalio Capital Management

Kinaset Therapeuticskinasettherapeutics.com in 𝕏Series A · Nov 2020 · $40M

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

Board Jamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investors5AM Ventures Atlas Venture RA Capital EQT Life Sciences Sixty Degree Capital Vivo Capital +3 more

Leica Microsystemsleica-microsystems.com in 𝕏

Leica Microsystems manufactures optical microscopy instruments and fluorescence reagents for scientific research and diagnostics.

BiotechDeep TechHardwareHealthtechMedical DevicesWetzlar, DE

Leitersleiters.com inSeed · Dec 2020

Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.

BiotechHealthtechMedical DevicesDenver, US

Co-investorsCorewell Health Ventures Escalate Capital Partners Frazier Healthcare Partners H.I.G. Capital H.I.G. HealthBridge Partners Kaiser Permanente Ventures +2 more

LoQus23loqus23.com in

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)in Caroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture Fund Dementia Discovery Fund Forbion

Miach Orthopaedicsmiachortho.com in

Miach Orthopaedics develops implants that help the body restore its own connective tissue, with an initial focus on treating ACL tears.

HealthtechMedical DevicesWestborough, US

Martha Murray(Founder)inChris Joyce(Executive Officer)in Patrick McBrayer(Executive Officer, Director)inSean Sansiveri(Director)Pieter Wolters(Director)

BoardMarc-Andre Marcotte(Director)

Co-investorsAmzak Health APERTURE Venture Partners Endeavour Vision

MindFramemindframe.care in

Mindframe builds AI-powered technology for behavioral health practitioners to enhance clinical care delivery and patient engagement in regulated healthcare environments.

AI & Machine LearningDigital HealthHealthtechMental HealthLondon, GB

Pinar Gorgulu(CEO & Co-founder)inFaye Cheung, PhD(CTO & Co-founder)in

Co-investorsTechstars

Montara Therapeuticsmontaratx.com in

Montara is a biotech company developing small-molecule therapeutics focused on neurodegeneration and diseases such as Alzheimer's.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Kevan Shokat(Co-Scientific Founder & Chairman of the SAB)Thomas Südhof(Co-Scientific Founder & SAB Member)Seth Stratton(Director)Dirk Langdorf(Director)Nicholas Hertz(Executive Officer, Director)

Co-investorsBEVC Two Bear Capital Dementia Discovery Fund Dolby Family Ventures KdT Ventures

MSTmst-sys.comMar 2026 · $40M

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAgate Medical Investments LP SCP Vitalife Partners Forbion GV (Google Ventures)Northpond Ventures

NanoPathnanopath.com in 𝕏Aug 2022 · $10M

Nanopath is developing a molecular diagnostic platform for point-of-care disease diagnosis, with a focus on women's health.

BiotechFemTechMedical DevicesCambridge, US

Alison Burklund(Executive Officer, Director)inAmogha Tadimety(Executive Officer, Director)in

Board Aaron Sandoski(Director)in Jeff Crowe(Director)in

Co-investorsNorwest Venture Partners Service Provider Capital Gingerbread Capital Medtech Convergence Norwich Ventures

Nflpanflpa.com

The NFLPA is the labor union representing players of the National Football League, working on their success and well-being both on and off the field.

Sports Tech

Nimbusnimbus.energySep 2022 · $125M

Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.

Deep TechEnergyHardware

Michael Gorman(Founder)in

Co-investorsFoothill Ventures Access Biotechnology Atlas Venture Bain Capital Life Sciences Biotechnology Value Fund Commodore Capital +2 more

Nimbusnimbusweb.me in 𝕏Sep 2022 · $125M

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPre-Seed to Succeed Yellow Rocks!Access Biotechnology Atlas Venture Bain Capital Life Sciences Biotechnology Value Fund +3 more

Nira Medicalniramedical.com in

Nira Medical consolidates independent neurology practices across the United States to improve patient access to neurological care.

Digital HealthHealthtechMedical Devices

Co-investorsSilversmith Capital Partners TRANSFORMATION CAPITAL

Nuwellisnuwellis.com in 𝕏

Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings.

BiotechHardwareHealthtechMedical DevicesEden Prairie, US

Rob Scott(Executive Officer)in Nestor Jaramillo, Jr.(Executive Officer, Director)inBrian Brown(Executive Officer)David A. Rosa(Executive Officer, Director)Claudia Drayton(Executive Officer)inDebra J. Kridner(Executive Officer)

Co-investorsAscension Ventures Kaiser Permanente Ventures

Onkos Surgicalonkossurgical.com in 𝕏Oct 2015

Onkos Surgical develops limb salvage and orthopedic reconstruction implants and systems for treating musculoskeletal cancer and complex orthopedic conditions.

HardwareHealthtechMedical DevicesParsippany, US

Patrick Treacy(Founder)inAntony Koblish(Director, Promoter)inBrad Tyler(Executive Officer)in

Board Adele Oliva(Director)in Stephen Bloch(Director)inPaul Touhey(Director)

Co-investors1315 Capital Canaan Partners JSD Capital, LLC

Ophthotechophthotech.comOct 2018

BiotechNew York, US

David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike Atieh inDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)

Co-investorsSofinnova Ventures Clarus SV Life Sciences

PanOpticapanopticapharma.com

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)

Board Abbie Celniker(Director)inDavid Guyer(Director)Bruce Peacock(Director)Kevin Starr(Director)inLutz Giebel(Director)

Co-investorsAstellas Venture Management LLC Agent Capital Third Rock Ventures

Perfuzeperfuze.com inFeb 2022

Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.

Deep TechHealthtechMedical DevicesGalway City, IE

Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in

Co-investorsSeroba Life Sciences Enterprise Ireland EQT Life Sciences

Pivot Point Consultingpivotpointconsulting.com in

Pivot Point Consulting provides managed IT services, EHR consulting, strategic advisory, analytics and AI solutions, and ERP implementation services to healthcare organizations.

AI & Machine LearningEnterprise SoftwareHealthtechSaaS

Podimetricspodimetrics.com in

Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)

Board Aaron Sandoski(Director)in

Co-investorsNorwich Ventures Scientific Health Development Polaris Partners Rock Health

Pulmocidepulmocide.com inDec 2022 · $52M

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant Capital F-Prime Capital Jeito Capital Longwood Fund SR One Capital Management Vivo Capital +2 more

Quralisquralis.com in 𝕏

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)in Shafique Virani(Executive Officer)in Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsDroia Ventures MC Healthcare Ventures Mission Biocapital Mitsui Global Investment Sanofi Ventures Amgen Ventures +7 more

Ria Healthriahealth.com in 𝕏Series A · Jul 2022 · $18M

Ria Health provides telemedicine-based treatment for alcohol and opioid use disorders, delivered by a team of physicians, nurse practitioners, and counselors.

Digital HealthHealthtechMental HealthWellness & FitnessSan Francisco, US

Bill Stapleton(CEO)in

Co-investorsSOSV

Ribometrixribometrix.com

BiotechGreenville, US

Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)

BoardMike Dial(Director)in

Co-investorsHatteras Venture Partners Illumina Ventures M Ventures MC Healthcare Ventures Pappas Capital AbbVie +2 more

Rondo Therapeuticsrondotx.com inMar 2022 · $67M

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.

BiotechHealthtech

Shelley Force Aldred(Co-Founder & Chief Executive Officer)in Nathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)

Co-investorsCanaan Partners Red Tree Venture Johnson & Johnson Innovation – JJDC Novo Holdings

Schweigerdermschweigerderm.com in

Schweiger Dermatology Group is a dermatology practice that provides medical and cosmetic dermatological services to patients, with locations across multiple areas and handling insurance billing, co-pays, and cosmetic procedures.

Digital HealthHealthtechMedical DevicesWellness & FitnessNew York, US

Dr. Eric Schweiger

Co-investorsLLR Lnk

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Corvia Medical Direct Flow Medical SkylitAccelecare HoldingsAeroCare Holdings, Inc.Affinium PharmaceuticalsAlantos PharmaceuticalsAlchemabAligned Telehealth IncAllegiance Hospice GroupAllianceCareAllos TherapeuticsAltura MedicalAptiv SolutionsAqueSysArchemixArgonaut TechnologiesArsanisArsanis BiosciencesAtopix Therapeutics LimitedAutifony TherapeuticsAuxilium PharmaceuticalsAxys PharmaceuticalsBioAgeBioCore HoldingsBioCore Holdings (BioClinica)BroadlaneCadent TechnologiesCardiac Support SystemsCardioKinetixCardioMindCellutionsCellzome LimitedCentauri HoldingsCerebral Vascular ApplicationsCHF SolutionsCibiemCognis HoldingConcentric MedicalConfluent Surgical, Inc.Convergence PharmaceuticalsCoral TherapeuticsCoreLab PartnersCRI WorldwideCumulusDoctors of Physical TherapyDualitasEasyChemEndlyzEntellusErvaxx LimitedESBATechEunoeEuro DentalversandEuro Dentalversand HoldingEUSA PharmaEyeBioEyetech PharmaceuticalsGeltex PharmaceuticalsGeneral Surgical InnovationsGenosisGlycoFi IncHalscionHealth Payment SystemsHealthifyHeritage Health SystemsHighTop HealthHPS/PayMedixIHG HoldingsIkano TherapeuticsImbria PharmaceuticalsIncyte PharmaceuticalsISG HoldingsJC NationwideJet HealthKalVista PharmaceuticalsKinetix PharmaceuticalsKuDOS PharmaceuticalsLeal TherapeuticsLenSx Lasers IncLeukoSite IncLipoSonixMaestro HealthcareMdeverywhereMedNovaMicromassMicroMedMicromet IncMisonixMpex PharmaceuticalsMyOrthosNeoVistaNeurogeneusNexanNimbus TherapeuticsNitrome BiosciencesNordic Consulting PartnersNovaLignOMS FoundationsOncoEthixOrchid ChemicalsOrthovitaPatient CarePelton & CranePhase ForwardPhysicians Dialysis Inc.PowderMed LtdPrileniaQuick Study RadiolRemita HealthRempex PharmaceuticalsRespiVert LtdRicerca BiosciencesRinat NeuroscienceRobling Medical IncSadra MedicalShire PharmaceuticalsSirona Dental Systems

Browse all 231 investments with full details →

▶31 more tracked companies

Sitryx Therapeutics LimitedSocios Mayores en SaludSoffio MedicalSolexa LtdSpectrum Professional ServicesSpinal Kinetics Spineology IncStimwaveStrides ArcolabSudo Bio Sun Behavioral HealthSynarcThe Corner PharmacyTheddfundThesan PharmaceuticalsThird Wave TechnologiesTLC VisionTransine Therapeutics LtdTransposonTRexBioTrialScopeTriangle PharmaceuticalsTrimTechU S Renal Care Urgent TeamVersicorVibrato Medical Violet Therapeutics, Inc.Vitalize Consulting SolutionsWellTheoryXimedica

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 15

9 IPOs · 6 acquisitions · showing 13

AdaptHealthNASDAQ: AHCOAlectorNASDAQ: ALECAmerican WellNYSE: AMWLBicycleNASDAQ: BCYCCytomed TherapeuticsNASDAQ: GDTCInsuletNASDAQ: PODDPulse BiosciencesNASDAQ: PLSESutrobioNASDAQ: STROXilio TherapeuticsNASDAQ: XLOAvitideacq. by RepligenCarawayacq. by MerckEyeBioacq. by MerckMisonixacq. by Bioventus

Portfolio news

latest coverage across their companies

AdaptHealth at Jefferies conference: focus shifts to scale and capitation By Investing.com

AdaptHealth · za.investing.com · Sep 14, 2026

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | BioPharma Dive

Nimbus · biopharmadive.com · Sep 11, 2026

Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com

Pulse Biosciences · investing.com · Sep 3, 2026

Nuwellis Highlights Aquadex Growth in Updated Presentation - TipRanks.com

Nuwellis · tipranks.com · Aug 26, 2026

Mitsubishi UFJ Asset Management Co. Ltd. Invests $26.41 Million in Insulet Corporation $PODD - Markets Daily

Insulet · themarketsdaily.com · Aug 21, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

The 19 Largest Global Startup Funding Rounds of July 2026 – AlleyWatch

AdvanCell · alleywatch.com · Aug 13, 2026

Truist raises American Well stock price target to $12 on EBITDA outlook By Investing.com

American Well · in.investing.com · Aug 13, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
SV Health Investors Growth Fund VII bLPs: New Mexico Educational Retirement Board	2024	—	0.0%	0.00x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 2

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Sutrobio	7.9%	$15.00	Sep 2018	$27.1M
American Well	—	$27.50	Jan 2021	$515.3K

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has SV Health Investors made?: SV Health Investors has 231 tracked investments, 15 of which have exited, including 13 dated in the last 24 months.
What stage does SV Health Investors invest at?: SV Health Investors invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is SV Health Investors's typical check size?: SV Health Investors typically writes checks of $1M – $20M.
What sectors does SV Health Investors focus on?: SV Health Investors focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is SV Health Investors located?: SV Health Investors is headquartered in Boston, US.
Does SV Health Investors lead rounds?: Yes, SV Health Investors leads investment rounds.
Who does SV Health Investors co-invest with?: SV Health Investors most often shares deals with Sanofi Ventures, Ascension Ventures, MRL Ventures Fund, among 138 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Medtech Venture Capital Insights with Paul LaViolette of SV Health Investors

State of MedTech · Paul LaViolette

Co-investors · 28

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 10

Xilio Therapeutics Alchemab Therapeutics Artios Pharma Imbria Imbria Pharmaceuticals Kinaset Therapeutics NimbusAlchemabNimbus Therapeuticsvisit www.enarabio.com

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 7

AdvanCell Draig Therapeutics Evidation Health Imbria Quralis Sudo Bio Therini Bio

$5M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 6

Alector Avitide Podimetrics QuralisArsanisTRexBio

$500K – $5M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 5

Bicycle Xilio Therapeutics Kinaset Therapeutics NimbusNimbus Therapeutics

$500K – $1M

Ascension Ventures

Ascension Ventures manages capital and presents itself as an investor connected to a large health system network, referencing hundreds of acute care hospitals and a substantial employee base.

Both backed · 5

Bardy Csa Medical Inc Nuwellis Ocular Therapeutix NasdoculConfluent Surgical, Inc.

$10M – $20M

M Ventures

M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.

Both backed · 5

Xilio Therapeutics Artios Pharma NRG Therapeutics Ribometrixvisit www.enarabio.com

$10.8M

Third Rock Ventures

Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.

Both backed · 4

Corvia Medical PanOpticaCibiemSoffio Medical

$100K – $5M

Dolby Family Ventures

Dolby Family Ventures is an investment firm focused on life sciences, backing companies across precision neuroscience and life sciences platforms.

Both backed · 4

Cerevance Montara Therapeutics Quralis Therini Bio

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 3

Adimab Alpheus Medical Avitide

$1M – $75M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 3

Artios Pharma Nitrome Biosciences Sitryx

$540K – $27M

Lightstone Ventures

Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.

Both backed · 3

Alchemab Therapeutics CerevanceNimbus Therapeutics

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

Both backed · 2

Xilio Therapeutics AdvanCell

$15M – $30M

▶16 more co-investors

7wire Ventures Omega Funds New Leaf Venture Partners Silversmith Capital Partners B Capital Group SOSV Summit Partners Aisling Capital Borealis Ventures McKesson Ventures Bain Capital Ventures US Venture Partners S32 Pivotal Life Sciences Sandbox Industries JUXTAPOSE VENTURES

Firms observed investing alongside SV Health Investors, from public investor directories. Shared companies are the overlap with SV Health Investors's recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M